Hepatitis E Diagnostic Tests Market: Global Industry Analysis and Forecast (2022-2029) by Test Type, End-Users, and Region

Hepatitis E Diagnostic Tests Market size was valued at USD 132.45 Million in 2021 and the total Hepatitis E Diagnostic Tests revenue is expected to grow at a CAGR of 3.8% from 2022 to 2029, reaching nearly USD 178.50 Million. According to the MMR analysis, the hepatitis E diagnostic tests market is expected to witness significant growth during the forecast period. The high prevalence rate of hepatitis E is due to factors such as limited access to essential water, lack of sanitation & hygiene, lack of nutritional foods, poor quality foods and poor health services has led to the demand for hepatitis E diagnostic tests across the developing countries. According to the World Health Organization (WHO), approximately 20 million people suffer from Hepatitis E each year, out of which 3.3 million are symptomatic cases and 56 600 hepatitis E-related deaths. In addition, increasing governmental initiatives, rising awareness about hepatitis diseases, increased tourism, and the introduction of novel diagnostic kits by major market players are further expected to be the major growth drivers for the hepatitis E diagnostic tests market. Hepatitis E is a liver inflammation caused by the hepatitis E virus (HEV). The Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis globally. HEV is spread by contaminated food and water. Hepatitis E is recognized as a travel-associated infection. The detection of viral RNA in the serum or feces is used to diagnose HEV. Hepatitis E has no particular therapy. HEV is detected through RNA analysis in biological materials such as feces, serum, and liver biopsy. The most significant ways of hepatitis virus prevention are good personal cleanliness, safe public water supply, efficient sanitary waste disposal, and food safety. According to WHO figures, an estimated 20 people die each year. According to WHO statistics, approximately 20 million people are infected by HEV each year, globally. Hepatitis E Diagnostic Tests MarketTo know about the Research Methodology :- Request Free Sample Report

Hepatitis E Diagnostic Tests Market Dynamics:

High prevalence of hepatitis E Hepatitis is a significant public health concern with a high prevalence rate globally, despite significant developments in medical interventions, vaccination coverage, and public awareness. Of all the hepatitis types, hepatitis E is the most prevalent and makes a significant contribution toward higher mortality rates. Globally, it is estimated that around 939 million people, or one in every eight, have been infected with HEV. Pigs are the primary reservoir for zoonotic HEV viruses. As a result, the consumption of pork and pork products has led to the risk of hepatitis E in individuals. Thus, the demand for hepatitis E diagnostic Tests has rapidly increased across the world, eventually increasing the hepatitis E diagnostic tests market growth during the forecast period. Globally, the epidemiological characteristics and clinical burden of HEV infection in the human population vary between countries/regions. It is fascinating to postulate whether this is associated with the specific prevalence rate of HEV in the local swine population and available pork products. HEV prevalence in farmed pigs varies significantly by country, ranging from 9.90% (Thailand, 95% CI 8.01-11.96) to 84.02% (India, 95% CI 44.05-100.00, I2 = 99%) of anti-HEV seroprevalence and 0% (Croatia, 95% CI 0.00-0.37) to 76.67% (Nigeria, 95% CI 67.32-84.89) of HEV RNA positivity. GT3 is found all over the world, whereas GT4 is mostly found in the Western Pacific region. GT3 and GT4 are interestingly co-circulating in countries/territories such as mainland China, Taiwan, Korea, and Japan. Despite the fact that GT3 HEV predominates in Europe, GT4 HEV has been detected in some unusual cases, including chronically infected people. Additionally, GT3 and GT4 are co-circulating in Belgian domestic pig populations. Lack of regulations for nucleic acid tests in emerging economies Lack of awareness about hepatitis diseases among the population, high cost of diagnostic tests, and inadequate reimbursement regulations are some factors that are expected to restrain the hepatitis E diagnostic tests market growth during the forecast period. In emerging countries, NAT is not mandatory because of the expensive nature of this test and the requirement of skilled personnel. By 2016, only 58 out of a total of 2,550 (2% of) blood banks in India performed NAT for hepatitis E diagnosis. In many developing countries, such as India and China, ELISA remains the only obligatory test, posing a significant barrier to NAT adoption. Blood screening in India includes serological testing for hepatitis surface antigens; however, there are no regulations for the use of NAT. As a result, there is a lack of clarity about findings among persons having hepatitis E diagnostic tests, which is a key limitation for the hepatitis E diagnostic tests market growth. Increasing biotechnology and biopharmaceutical industries The biotechnology and biopharmaceutical industries have a significant demand for immunoassay kits and reagents. As a result, the increase of such industries is expected to accelerate the growth of the hepatitis E diagnostic tests market during the forecast period. The increase in the end-user population in these industries has driven many organizations to introduce new products and investment in creating better-quality products. Because immunoassays are used at numerous phases, from product development and manufacturing to quality control in production, this is regarded as a favorable sign for market growth.

Hepatitis E Diagnostic Tests Market Segment Analysis:

Based on the test type, the ELISA HEV IgM Test kits segment dominated the global hepatitis E diagnostic tests market with the highest market share of 32.8% in 2021. The segment is expected to grow at a CAGR of 3.78% during the forecast period and maintain its dominance by 2029. The increased use of HEV-IgM ELISA test kits in clinical laboratories is expected to be the primary growth driver for the segment. In addition, these test kits are rapidly adopted for research and in vitro diagnostic purposes. HEV-IgM is a rapid, self-performing, immunochromatographic assay for the detection of IgM antibodies to the Hepatitis E virus in human serum/plasma. HEV-IgM ELISA is an enzyme-linked immunosorbent test used to detect IgM-class antibodies to the hepatitis E virus in human serum or plasma. It is designed for use in clinical laboratories for the diagnosis and treatment of patients with hepatitis E virus infection. An estimated 20 million HEV infections occur each year, resulting in about three million clinical cases and 70,000 mortality. Infected individuals follow a normal serological pattern, with IgM antibodies initially appearing, followed by IgG seroconversion. The number of IgM antibodies drops fast during the acute phase, and subsequently, more long-lasting IgG antibodies appear for up to 14 years. As a result, the demand for ELISA HEV IgM Test kits has rapidly increased across the end-users. Hepatitis E Diagnostic Tests Market 1 The ELISA HEV IgG Test kits segment is expected to grow at a CAGR of 3.12% during the forecast period. Anti-HEV antigen (Ag)-specific ELISA is now commercially accessible as a low-cost alternative to PCR. HEV IgG Antibody ELISA is a quick and easy method for detecting IgG antibodies to Hepatitis E Virus (HEV) in human serum or plasma. The RT-PCR Test kits segment is expected to grow at a moderate rate during the forecast period. The use of this method of HEV detection is mostly due to its sensitivity and specificity. This method is frequently used for in vitro diagnostic applications, however, it is a somewhat costly method that requires a suite of controls to verify that they have been conducted correctly. As a result, the RT-PCR method's usage is significantly reduced, resulting in a moderate growth rate for the segment.

Hepatitis E Diagnostic Tests Market Regional Insights:

The Asia-Pacific region dominated the global hepatitis E Diagnostic Tests market with the highest revenue share in terms of both value and volume in 2021. The high prevalence rate of various infectious diseases in the region is expected to be the primary factor responsible for Hepatitis. As a result, the demand for diagnostic tests is increased rapidly in the region. The Hepatitis E virus (HEV) is a leading cause of hepatitis, causing considerable morbidity and mortality in developing countries such as Bangladesh. Hepatitis E infection is frequent in low- and middle-income countries, because of insufficient access to the necessary water, lack of sanitation, hygiene, and poor health services, such as in South Asia, and Central and Middle Asia. In these countries, the virus emerges as outbreaks as well as sporadic cases. As a result, the sales of hepatitis E diagnostic Tests are significantly increased, leading to an increase in the revenue share of the market in the region. In addition, the rapidly increasing geriatric population, increasing pork consumption, high adoption of Hepatitis E tests, increasing awareness among the population regarding the diagnosis of hepatitis, and advanced product launches by the market players in the region are some other factors that are expected to boost the hepatitis E diagnostic tests market growth during the forecast period. Hepatitis E Diagnostic Tests Market 2India is expected to hold the largest market share of 37.8% by 2029. According to the MMR analysis, approximately 60% of blood donors in India have circulating anti-HEV IgG antibodies, indicating past viral exposure, indicating that HEV infection and disease are extremely prevalent in the country. The frequencies of seroprevalence vary by age, with older persons having higher rates. 5 Hepatitis E is responsible for about half of all cases of acute hepatitis and a corresponding number of cases of acute liver failure (ALF). This factor is expected to increase hepatitis diagnostic tests in the country, leading to an increase the market growth. Meanwhile, the majority of India's pigs are situated in the country's central and northern zones. In 2019, Assam had almost two million pigs. Because pigs are regarded to be the primary carrier of HEV, the high pork consumption shows that the illness is spread via zoonotic agents. As a result, it has increased the demand for hepatitis E diagnostic tests and increased the hepatitis E diagnostic Tests market growth in the country.

Hepatitis E Diagnostic Tests Market Scope: Inquiry Before Buying

Hepatitis E Diagnostic Tests Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: USD 132.45 Million.
Forecast Period 2022 to 2029 CAGR: 3.8 % Market Size in 2029: USD 178.50 Million.
Segments Covered: by Test Type • ELISA HEV IgM Test kits • ELISA HEV IgG Test kits • RT-PCR Test kits • Other
by End-user • Hospitals • Research Centers • Diagnostic Laboratories • Point of Care • Other

Hepatitis E Diagnostic Tests Market, by Region

• North America o United States o Canada o Mexico • Europe o UK o France o Germany o Italy o Spain o Sweden o Austria o Rest Of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest Of APAC • Middle East and Africa o South Africa o GCC o Egypt o Nigeria o Rest Of ME&A • South America o Brazil o Argentina o Rest Of South America

Hepatitis E Diagnostic Tests Market Key Palayers

• Chemeurope (EU) • Roche Holding AG (Switzerland) • Fortress Diagnostics (United Kingdom) • Altona Diagnostics GmbH (Germany) • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) • Biokit S.A. (Spain) • F. Hoffmann-La Roche Ltd. (Switzerland) • Dia.Pro - Diagnostic Bioprobes s.r.l (Italy) • Fast-track diagnostics Ltd. (Luxembourg) • Fortress Diagnostics Limited (Ireland) • Mikrogen GmBH (Germany) • MP Biomedicals, LLC. (California) • Primerdesign Ltd. (United Kingdom) • PerkinElmer, Inc. (United States) • ELITechGroup (France) • Diagnostic Automation/Cortez Diagnostics, Inc., (California) • ORGENTEC Diagnostika (Germany) • EUROIMMUN Medizinische Labordiagnostika AG. (Germany) • Abbott Laboratories (United States) • Siemens Ag, (Germany) FAQs: 1. What is the major growth driver for the Hepatitis E Diagnostic Tests market? Ans. The high prevalence rate of hepatitits E is expected to be the major driver for the Hepatitis E Diagnostic Tests market. 2. What is the major restraint for the Hepatitis E Diagnostic Tests market growth? Ans. The lack of skilled professionals are expected to be the major restraining factor for the Hepatitis E Diagnostic Tests market growth. 3. Which region is expected to lead the global Hepatitis E Diagnostic Tests market during the forecast period? Ans. The Asia-Pacific market is expected to lead the global Hepatitis E Diagnostic Tests market during the forecast period due to high prevalence rate of hepatitis E in the region. 4. What is the projected market size & growth rate of the Hepatitis E Diagnostic Tests Market? Ans. The Hepatitis E Diagnostic Tests Market size was valued at USD 132.45 Million in 2021 and the total Hepatitis E Diagnostic Tests revenue is expected to grow at a CAGR of 3.8% from 2022 to 2029, reaching nearly USD 178.50 Million. 5. What segments are covered in the Hepatitis E Diagnostic Tests Market report? Ans. The segments covered in the Hepatitis E Diagnostic Tests market report are Test Type, End-user, and Region.
1. Global Hepatitis E Diagnostic Tests Market: Research Methodology 2. Global Hepatitis E Diagnostic Tests Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Hepatitis E Diagnostic Tests Market 2.2. Summary 2.2.1. Absolute Opportunities 2.2.2. Key Findings 2.2.4. Industry Recommendations 3. Global Hepatitis E Diagnostic Tests Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact On the Market 4. Global Hepatitis E Diagnostic Tests Market Segmentation 4.1. Global Hepatitis E Diagnostic Tests Market, by Test Type (2021-2029) • ELISA HEV IgM Test kits • ELISA HEV IgG Test kits • RT-PCR Test kits • Other 4.2. Global Hepatitis E Diagnostic Tests Market, by End-user (2021-2029) • Hospitals • Research Centers • Diagnostic Laboratories • Point of Care • Other 5. North America Hepatitis E Diagnostic Tests Market(2021-2029) 5.1 North American Hepatitis E Diagnostic Tests Market, By Test Type (2021-2029) • ELISA HEV IgM Test kits • ELISA HEV IgG Test kits • RT-PCR Test kits • Other 5.2 North America Hepatitis E Diagnostic Tests Market, By End-user (2021-2029) • Hospitals • Research Centers • Diagnostic Laboratories • Point of Care • Other 5.3 North America Hepatitis E Diagnostic Tests Market, by Country (2021-2029) • United States • Canada • Mexico 6. European Hepatitis E Diagnostic Tests Market (2021-2029) 6.1. European Hepatitis E Diagnostic Tests Market, By Test Type (2021-2029) 6.2. European Hepatitis E Diagnostic Tests Market, By End-user (2021-2029) 6.3 European Hepatitis E Diagnostic Tests Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Hepatitis E Diagnostic Tests Market (2021-2029) 7.1. Asia Pacific Hepatitis E Diagnostic Tests Market, By Test Type (2021-2029) 7.2. Asia Pacific Hepatitis E Diagnostic Tests Market, By End-user (2021-2029) 7.3. Asia Pacific Hepatitis E Diagnostic Tests Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Hepatitis E Diagnostic Tests Market (2021-2029) 8.1. Middle East and Africa Hepatitis E Diagnostic Tests Market, By Test Type (2021-2029) 8.2. Middle East and Africa Hepatitis E Diagnostic Tests Market, By End-user (2021-2029) 8.3. Middle East and Africa Hepatitis E Diagnostic Tests Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Hepatitis E Diagnostic Tests Market (2021-2029) 9.1. South America Hepatitis E Diagnostic Tests Market, By Test Type (2021-2029) 9.2. South America Hepatitis E Diagnostic Tests Market, By End-user (2021-2029) 9.3 South America Hepatitis E Diagnostic Tests Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Chemeurope (EU) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Roche Holding AG (Switzerland) 10.3 Fortress Diagnostics (United Kingdom) 10.4 Altona Diagnostics GmbH (Germany) 10.5 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China) 10.6 Biokit S.A. (Spain) 10.7 F. Hoffmann-La Roche Ltd. (Switzerland) 10.8 Dia.Pro - Diagnostic Bioprobes s.r.l (Italy) 10.9 Fast-track diagnostics Ltd. (Luxembourg) 10.10 Fortress Diagnostics Limited (Ireland) 10.11 Mikrogen GmBH (Germany) 10.12 MP Biomedicals, LLC. (California) 10.13 Primerdesign Ltd. (United Kingdom) 10.14 PerkinElmer, Inc. (United States) 10.15 ELITechGroup (France) 10.16 Diagnostic Automation/Cortez Diagnostics, Inc., (California) 10.17 ORGENTEC Diagnostika (Germany) 10.18 EUROIMMUN Medizinische Labordiagnostika AG. (Germany) 10.19 Abbott Laboratories (United States) 10.20 Siemens Ag, (Germany)

About This Report

Report ID 171601
Category Healthcare
Published Date Jan 2023
Updated Date
Contact Us